Laser Treatment for Vulvar Lichen Sclerosus
Primary Purpose
Vulvar Lichen Sclerosus
Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ablative Fractional 2940 nm Laser
Sponsored by
About this trial
This is an interventional treatment trial for Vulvar Lichen Sclerosus focused on measuring Massachusetts residents
Eligibility Criteria
We are currently recruiting Massachusetts residents only due to COVID-19.
Inclusion Criteria:
- Female
- Aged 18 years old or older
- Biopsy-proven active vulvar lichen sclerosus
- Characteristic changes of vulvar lichen sclerosus on gynecological exam
Self-reported indication of one or more of the following symptoms of lichen sclerosus
- Dryness
- Itching
- Burning
- Bleeding
- Blistering
- Soreness
- Easily bruises
- Easily tears
- Ulcerated lesions
- Painful intercourse
- Ability to complete questionnaires in English
- Written, informed consent
- Willing and able to logistically follow schedule of treatments and follow-up visits
Exclusion Criteria:
- Receiving systemic immunosuppressant's (e.g. corticosteroids) within 4 weeks of enrollment
- Use of topical vulvar steroid-containing creams at the affected area within 4 weeks of enrollment
- Immunocompromised (e.g. lymphoma, AIDS, Wiskott-Aldrich syndrome)
- History of uncontrolled malignant disease
- Additional genital skin disease
- Known allergy or intolerance to topical anesthesia
- Known history of connective tissue disease
- Known propensity for keloid formations
Sites / Locations
- BIDMC
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Intervention
Arm Description
Women with biopsy-proven lichen sclerosus will be treated with the ProFractional hand piece using the sapphire plate stand-off (Sciton, Inc. Palo, Alto, CA). The laser energy is delivered in a scanning fractional pattern to ablate microchannels in tissue to allow faster healing. Treatment will be delivered in 3 sessions scheduled 4 weeks (+/- 1 week) apart
Outcomes
Primary Outcome Measures
Change in histology and depth of disease from baseline to three months after the last laser treatment
The baseline depth of lichen sclerosus will be based on the results of the clinical biopsy performed before study participation. The investigators will use the study biopsy collected at the follow-up visit three months after the last treatment to determine resolution of disease or, if disease persists, to what depth. The biopsies will therefore serve as an objective means to determine effective treatment of disease.
Secondary Outcome Measures
Change in symptoms and quality of life using the Vulvovaginal Symptom Questionnaire (VSQ)
The VSQ is a 21-item written questionnaire with four scales: symptoms, emotions, life-impact, and sexual impact. Each item is assessed with yes or no questions. If a participant answers no, they receive a score of 0, and if the participant answers yes, they receive a score of 1 for each question. The results are added to a composite score.
Minimum score (better outcome): 0 Maximum score (worse outcome): 21
Change in symptoms using the Patient Global Impression Scale of Change (PGIC)
The PGIC is a written questionnaire to assess change in status or symptoms over time. Patients can say that their symptoms are: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6) or very much worse (7).
Minimum score (better outcome): 1 Maximum score (worse outcome): 7
Change in symptom severity using the Patient Global Impression Scale of Severity (PGIS)
The PGIs is a written questionnaire to assess current status or symptoms. Patients can say that their symptoms are: normal (1), mild (2), moderate (3), or severe (4).
Minimum score (better outcome): 1 Maximum score (worse outcome): 4
Vulvar lichen sclerosus improvement as assessed using photographs
Photographs will be rated by observers blinded to whether a photo is before or after treatment
Satisfaction with treatment using a participant satisfaction questionnaire
Using a written questionnaire, patients will be asked how satisfied they were with the treatment. They can choose that they are extremely satisfied (1), somewhat satisfied (2), neither satisfied nor dissatisfied (3), somewhat dissatisfied (4), or extremely dissatisfied (5).
Minimum score (better outcome): 1 Maximum score (worse outcome): 5
Full Information
NCT ID
NCT04134494
First Posted
October 17, 2019
Last Updated
May 27, 2022
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Sciton
1. Study Identification
Unique Protocol Identification Number
NCT04134494
Brief Title
Laser Treatment for Vulvar Lichen Sclerosus
Official Title
Effectiveness of Ablative Fractional 2940 nm Laser Treatment for Vulvar Lichen Sclerosus
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 1, 2020 (Actual)
Primary Completion Date
May 27, 2022 (Actual)
Study Completion Date
October 7, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Sciton
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
The object of this non-randomized, prospective study is to assess the effectiveness of ablative fractional 2940 nm laser treatment of vulvar lichen sclerosus.
Aim 1: To assess physical and histological changes related to vulvar lichen sclerosus before and after laser treatment.
Aim 2: To evaluate participant satisfaction for laser treatment of vulvar lichen sclerosus.
The results of this study will determine whether fractional 2940 nm laser is an effective treatment option for lichen sclerosus, particularly for those participants not eligible for high-dose topical steroids or who have failed prior treatment with topical steroids.
Detailed Description
This will be a non-randomized, open-label, prospective study. Participants will be recruited in general and subspecialty obstetrics and gynecology clinics. Participants who meet all eligibility criteria, including providing written informed consent, will have three treatment visits and three follow-up visits in an outpatient setting. Participants will not be charged for any treatments.
At each treatment visit, participants will be asked to complete questionnaires to assess their symptoms. The investigators will also take photographs of the affected area at each treatment visit. Photographs will include only the area of lichen sclerosus, such that individuals cannot be identified in the photographs. Participant photographs will be taken using the BIDMC PhotoConsult iOS application that allows providers to upload photographs to a patient's online medical record through a secure application.
Women with biopsy-proven lichen sclerosus will be treated with the ProFractional hand piece using the sapphire plate stand-off (Sciton, Inc. Palo, Alto, CA). The laser energy is delivered in a scanning fractional pattern to ablate microchannels in tissue to allow faster healing. Treatment will be delivered in 3 sessions scheduled 4 weeks (+/- 1 week) apart.
Prior to receiving treatment, topical 4% lidocaine anesthetic will be applied to the affected area for 20-30 minutes and then wiped away. The treatment area will be cleaned and dried of any moisture prior to treatment. The disinfected standoff with sapphire plate will then be applied to the ProFractional hand piece. Based on the biopsy results, the appropriate ablation depth will be inputted with 11% treatment density selected. Each treatment will include two passes of the laser over the affected area.
Treatment visit 1, month 0: On the first pass, the depth of the laser will be from 300 to 500 microns, or the thickness of 3 to 5 sheets of paper; the depth will be based on the biopsy that was used to diagnosis the lichen sclerosus. On the second pass, the depth will be 50 microns deeper than the first pass and the hand piece rotated 45˚.
Treatment visit 2, month 1: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.
Treatment visit 3, month 2: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.
Participants will return for follow-up visits at 1, 3, and 6 months (months 3, 6 and 9 of the study) following the third treatment.
Follow-up visit 1, month 3
Participants will be asked to complete questionnaires to assess outcomes.
The investigators will take photographs of the affected area.
Follow-up visit 2, month 6
Participants will be asked to complete questionnaires to assess outcomes.
The investigators will take photographs of the affected area.
Biopsy of area with lichen sclerosus; the biopsy will be done the same way as the one that was done to diagnosis your lichen sclerosus
Follow-up visit 6, month 9
Participants will be asked to complete questionnaires to assess outcomes.
The investigators will take photographs of the affected area.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vulvar Lichen Sclerosus
Keywords
Massachusetts residents
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
A single group of 30 patients with biopsy-proven Lichen sclerosus will be treated on a monthly basis for 3 months. Biopsy to be repeated at month #6. The biopsy from before treatment will be compared with biopsies after treatment.
Masking
None (Open Label)
Masking Description
No masking will be used as all patients will receive the treatment.
Allocation
N/A
Enrollment
14 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Women with biopsy-proven lichen sclerosus will be treated with the ProFractional hand piece using the sapphire plate stand-off (Sciton, Inc. Palo, Alto, CA). The laser energy is delivered in a scanning fractional pattern to ablate microchannels in tissue to allow faster healing. Treatment will be delivered in 3 sessions scheduled 4 weeks (+/- 1 week) apart
Intervention Type
Device
Intervention Name(s)
Ablative Fractional 2940 nm Laser
Intervention Description
Treatment visit 1, month 0: On the first pass, the depth of the laser will be from 300 to 500 microns, or the thickness of 3 to 5 sheets of paper; the depth will be based on the biopsy that was used to diagnosis the lichen sclerosus. On the second pass, the depth will be 50 microns deeper than the first pass and the hand piece rotated 45˚.
Treatment visit 2, month 1: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.
Treatment visit 3, month 2: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.
Primary Outcome Measure Information:
Title
Change in histology and depth of disease from baseline to three months after the last laser treatment
Description
The baseline depth of lichen sclerosus will be based on the results of the clinical biopsy performed before study participation. The investigators will use the study biopsy collected at the follow-up visit three months after the last treatment to determine resolution of disease or, if disease persists, to what depth. The biopsies will therefore serve as an objective means to determine effective treatment of disease.
Time Frame
From enrollment to 9 month follow up visit
Secondary Outcome Measure Information:
Title
Change in symptoms and quality of life using the Vulvovaginal Symptom Questionnaire (VSQ)
Description
The VSQ is a 21-item written questionnaire with four scales: symptoms, emotions, life-impact, and sexual impact. Each item is assessed with yes or no questions. If a participant answers no, they receive a score of 0, and if the participant answers yes, they receive a score of 1 for each question. The results are added to a composite score.
Minimum score (better outcome): 0 Maximum score (worse outcome): 21
Time Frame
From enrollment to 9 month follow up visit
Title
Change in symptoms using the Patient Global Impression Scale of Change (PGIC)
Description
The PGIC is a written questionnaire to assess change in status or symptoms over time. Patients can say that their symptoms are: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6) or very much worse (7).
Minimum score (better outcome): 1 Maximum score (worse outcome): 7
Time Frame
From enrollment to 9 month follow up visit
Title
Change in symptom severity using the Patient Global Impression Scale of Severity (PGIS)
Description
The PGIs is a written questionnaire to assess current status or symptoms. Patients can say that their symptoms are: normal (1), mild (2), moderate (3), or severe (4).
Minimum score (better outcome): 1 Maximum score (worse outcome): 4
Time Frame
From enrollment to 9 month follow up visit
Title
Vulvar lichen sclerosus improvement as assessed using photographs
Description
Photographs will be rated by observers blinded to whether a photo is before or after treatment
Time Frame
From enrollment to 9 month follow up visit
Title
Satisfaction with treatment using a participant satisfaction questionnaire
Description
Using a written questionnaire, patients will be asked how satisfied they were with the treatment. They can choose that they are extremely satisfied (1), somewhat satisfied (2), neither satisfied nor dissatisfied (3), somewhat dissatisfied (4), or extremely dissatisfied (5).
Minimum score (better outcome): 1 Maximum score (worse outcome): 5
Time Frame
From enrollment to 9 month follow up visit
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
We are currently recruiting Massachusetts residents only due to COVID-19.
Inclusion Criteria:
Female
Aged 18 years old or older
Biopsy-proven active vulvar lichen sclerosus
Characteristic changes of vulvar lichen sclerosus on gynecological exam
Self-reported indication of one or more of the following symptoms of lichen sclerosus
Dryness
Itching
Burning
Bleeding
Blistering
Soreness
Easily bruises
Easily tears
Ulcerated lesions
Painful intercourse
Ability to complete questionnaires in English
Written, informed consent
Willing and able to logistically follow schedule of treatments and follow-up visits
Exclusion Criteria:
Receiving systemic immunosuppressant's (e.g. corticosteroids) within 4 weeks of enrollment
Use of topical vulvar steroid-containing creams at the affected area within 4 weeks of enrollment
Immunocompromised (e.g. lymphoma, AIDS, Wiskott-Aldrich syndrome)
History of uncontrolled malignant disease
Additional genital skin disease
Known allergy or intolerance to topical anesthesia
Known history of connective tissue disease
Known propensity for keloid formations
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roger Lefevre, MD
Organizational Affiliation
Beth Israel Deaconess Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
BIDMC
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Laser Treatment for Vulvar Lichen Sclerosus
We'll reach out to this number within 24 hrs